^
HLA-A*02:01
Uveal Melanoma
ipilimumab + tebentafusp
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HLA-A*02:01
Uveal Melanoma
tebentafusp
Sensitive
:
A1
No biomarker
Uveal Melanoma
TC
Sensitive
:
A2
No biomarker
Uveal Melanoma
pembrolizumab
Sensitive
:
A2
No biomarker
Uveal Melanoma
nivolumab
Sensitive
:
A2
No biomarker
Uveal Melanoma
ipilimumab
Sensitive
:
A2
No biomarker
Uveal Melanoma
dacarbazine
Sensitive
:
A2
No biomarker
Uveal Melanoma
temozolomide
Sensitive
:
A2
No biomarker
Uveal Melanoma
trametinib
Sensitive
:
A2
No biomarker
Uveal Melanoma
paclitaxel
Sensitive
:
A2
No biomarker
Uveal Melanoma
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Uveal Melanoma
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Uveal Melanoma
CaT
Sensitive
:
A2
HLA-A2 positive
Uveal Melanoma
tebentafusp
Sensitive
:
B
GNA11 mutation
Uveal Melanoma
selumetinib
Sensitive
:
C2
GNAQ mutation
Uveal Melanoma
trametinib
Sensitive
:
C2
MBD4 mutation
Uveal Melanoma
nivolumab
Sensitive
:
C3
CXCL10 elevation
Uveal Melanoma
tebentafusp
Sensitive
:
C3
GNAQ mutation
Uveal Melanoma
pembrolizumab
Sensitive
:
C3
GNA11 mutation
Uveal Melanoma
pembrolizumab
Sensitive
:
C3
GNA11 Q209L
Uveal Melanoma
IDE196
Sensitive
:
C3
LDH-H
Uveal Melanoma
nivolumab
Sensitive
:
C3
LDH-H
Uveal Melanoma
pembrolizumab
Sensitive
:
C3
GNAQ mutation
Uveal Melanoma
cabozantinib capsule
Sensitive
:
C3
GNAQ mutation
Uveal Melanoma
AEB071
Sensitive
:
C3
GNA11 mutation
Uveal Melanoma
AEB071
Sensitive
:
C3
LDH-H
Uveal Melanoma
ipilimumab
Sensitive
:
C3
GNAQ Q209L
Uveal Melanoma
selumetinib
Sensitive
:
C3
GNA11 Q209L
Uveal Melanoma
selumetinib
Sensitive
:
C3
GNA11 mutation
Uveal Melanoma
cabozantinib capsule
Sensitive
:
C3
DDX43 overexpression
Uveal Melanoma
selumetinib
Resistant
:
C3
KRAS overexpression
Uveal Melanoma
selumetinib
Resistant
:
C3
NRAS overexpression
Uveal Melanoma
selumetinib
Resistant
:
C3